Abivax (ABVX) is down 14.2% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is continued investor caution after the company’s June 1 Phase 3 maintenance update for obefazimod in ulcerative colitis. While the efficacy results were strong, the market has remained focused on unresolved safety debate around the dataset, and with no fresh company announcement visible today, this looks more like follow-through selling than a brand-new catalyst.
Details:
Abivax said both the 25 mg and 50 mg obefazimod arms met the primary endpoint in the Phase 3 ABTECT maintenance trial, with remission rates well above placebo at Week 44.Despite the positive topline efficacy, investors have been digesting safety-related concerns tied to the broader readout, which has kept sentiment volatile through June.The company’s recent materials still point to a planned late-2026 U.S. filing for obefazimod in ulcerative colitis, so the stock appears to be trading on risk reassessment rather than on a change to the regulatory timeline.Abivax also completed a $45 million ADS offering in May tied to a royalty-certificate repurchase, leaving dilution and capital structure in the background as additional factors traders may still be considering.Sources:
Abivax, BioPharma Dive, SEC
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
Quiver Alerts
Receive ABVX Data Alerts
Get market-moving data, filings, and signals for ABVX in real time.
Sign Up
$ABVX Hedge Fund Activity
We have seen 159 institutional investors add shares of $ABVX stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 1,771,418 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $197,247,394
- MORGAN STANLEY removed 1,447,036 shares (-45.9%) from their portfolio in Q1 2026, for an estimated $161,127,458
- DEUTSCHE BANK AG\ removed 764,899 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,171,503
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 713,434 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $96,210,142
- PARADIGM BIOCAPITAL ADVISORS LP removed 645,000 shares (-45.5%) from their portfolio in Q1 2026, for an estimated $71,820,750
- TCG CROSSOVER MANAGEMENT, LLC removed 630,511 shares (-8.9%) from their portfolio in Q1 2026, for an estimated $70,207,399
- CORMORANT ASSET MANAGEMENT, LP removed 590,000 shares (-43.7%) from their portfolio in Q1 2026, for an estimated $65,696,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ABVX Analyst Ratings
Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.
$ABVX Price Targets
Multiple analysts have issued price targets for $ABVX recently. We have seen 7 analysts offer price targets for $ABVX in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $150.0 on 06/16/2026
- David Nierengarten from Wedbush set a target price of $90.0 on 06/02/2026
- Jason N. Butler from Citizens set a target price of $187.0 on 06/02/2026
- Faisal Khurshid from Jefferies set a target price of $90.0 on 06/02/2026
- Judah Frommer from Morgan Stanley set a target price of $132.0 on 06/02/2026
- Gregory Renza from Truist Securities set a target price of $135.0 on 06/02/2026
- Etzer Darout from Barclays set a target price of $148.0 on 03/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Abivax Slides as Investors Continue to Weigh Obefazimod Safety Questions
Abivax (ABVX) is down 14.2% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is continued investor caution after the company’s June 1 Phase 3 maintenance update for obefazimod in ulcerative colitis. While the efficacy results were strong, the market has remained focused on unresolved safety debate around the dataset, and with no fresh company announcement visible today, this looks more like follow-through selling than a brand-new catalyst.
Details:
Sources:
Abivax, BioPharma Dive, SEC
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$ABVX Hedge Fund Activity
We have seen 159 institutional investors add shares of $ABVX stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ABVX Analyst Ratings
Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.
$ABVX Price Targets
Multiple analysts have issued price targets for $ABVX recently. We have seen 7 analysts offer price targets for $ABVX in the last 6 months, with a median target of $135.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »